ARTV
Artiva Biotherapeutics, Inc.Healthcare·Biotechnology
$7.93
$196M market cap
Revenue
$0.0M
Free Cash Flow
$-36.3M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/mi
2-Year Price History
$7.87-34.4%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -23.8 | -24.4 | -23.5 | -21.0 | -21.2 | -0.2 | 86.8 | 10.3 | 24.7 | -419.0% | -- | -- |
| Act | 2025-Q4 | 0.0 | -21.3 | -21.9 | -20.8 | -14.7 | -15.2 | -0.4 | 108.0 | 10.9 | 24.4 | -187.9% | -- | -- |
Valuation & Metrics
Market Stats
Price$7.93
Market Cap$196M
Enterprise Value$119M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-18.5%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-44.3M
Free Cash Flow$-36.3M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-303.5%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.2M
Days to Cover1.0
Change (vs Prior)+54.8%
Need at least 2 settlement dates for chart
Employees
Headcount96
Revenue / Employee$0
Gross Profit / Employee$-6,938
Cash Runway
28.7months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
52.5%(+25.2% YoY)
32 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
2.0%(-2.3% YoY)
7 filers
Vanguard, iShares, SPDR
Market makers
0.1%(+0.1% YoY)
1 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $63.5M | $15.45 | +$0 | +$0 | -4.3% | $9.44B |
| 5AM Venture Management, LLC | $15.2M | $15.45 | +$0 | +$0 | +1.3% | $360M |
| VR Adviser, LLC | $10.4M | $15.45 | +$0 | +$0 | -1.8% | $2.68B |
| venBio Partners LLC | $3.4M | $15.45 | −$755K | −$4.3M | -2.2% | $281M |
| FRANKLIN RESOURCES INC | $3.4M | $15.45 | +$0 | +$0 | -0.2% | $403.03B |
| Revelation Capital Management, LLC | $1.9M | $4.29 | +$0 | +$1.9M | -24.0% | $67.4M |
| BlackRock, Inc.Passive | $1.4M | $12.56 | +$5K | −$6.6M | -0.2% | $5.69T |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $1.3M | $6.44 | +$1.3M | +$1.3M | — | $4.04T |
| WELLINGTON MANAGEMENT GROUP LLP | $1.3M | $15.45 | +$0 | +$0 | -0.3% | $533.98B |
| Propel Bio Management, LLC | $950K | $6.44 | +$943K | +$950K | -2.9% | $159M |
| MILLENNIUM MANAGEMENT LLC | $794K | $1.51 | −$604K | +$794K | -0.5% | $127.40B |
| TWO SIGMA INVESTMENTS, LP | $741K | $3.88 | −$192K | +$741K | -0.9% | $117.03B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $655K | $12.48 | +$4K | −$2.0M | +2.3% | $1.61T |
| Alyeska Investment Group, L.P. | $644K | $15.45 | +$0 | +$0 | -0.5% | $35.33B |
| RENAISSANCE TECHNOLOGIES LLC | $515K | $3.32 | −$233K | +$515K | +1.2% | $63.91B |
| JANE STREET GROUP, LLCMM | $254K | $1.51 | −$8K | +$254K | -0.1% | $92.10B |
| STATE STREET CORPPassive | $231K | $12.50 | +$0 | −$876K | -0.2% | $2.89T |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $225K | $1.51 | +$0 | +$225K | -2.3% | $4.93B |
| VANGUARD FIDUCIARY TRUST COPassive | $211K | $6.44 | +$211K | +$211K | — | $395.83B |
| PANAGORA ASSET MANAGEMENT INC | $198K | $6.44 | +$198K | +$198K | +0.0% | $26.69B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-3.33%
avg per quarter
Holders (ex-self)
-3.20%
excl. this stock
Buyers (this Q)
-2.18%
12 buyers · $0.00B in
Sellers (this Q)
+0.55%
15 sellers · $0.00B out
alpha coverage: 99% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-3.1%
how holders react when this stock falls
On quiet Qs
-2.1%
−10% to +10% baseline
On rallies (+10%+)
-4.0%
how they react when this stock rises
Holders' portfolio flow this Q
-3.9%
outflows — trims may be forced
Sellers' portfolio flow this Q
-10.0%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
+0.4%
Holder mid (any stock)
-2.1%
Holder rally (any stock)
+0.0%
Biggest decreases this quarter
venBio Partners LLC−$755Kα-2.2MILLENNIUM MANAGEMENT LLC−$604Kα-0.5MARSHALL WACE, LLPexited−$341KRENAISSANCE TECHNOLOGIES LLC−$233Kα+1.2TWO SIGMA INVESTMENTS, LP−$192Kα-0.9Scientech Research LLCexited−$119KPRELUDE CAPITAL MANAGEMENT, LLCexited−$46KJANE STREET GROUP, LLC−$8Kα-0.1Tower Research Capital LLC (TRC)exited−$5KBANK OF AMERICA CORP /DE/exited−$0
New buyers this quarter
VANGUARD CAPITAL MANAGEMENT LLC+$0.00BPropel Bio Management, LLC+$0.00Bα-2.9VANGUARD FIDUCIARY TRUST CO+$0.00BPANAGORA ASSET MANAGEMENT INC+$0.00Bα+0.0Velan Capital Investment Management LP+$0.00Bα-5.3Simplify Asset Management Inc.+$0.00Bα-1.4Sanctuary Advisors, LLC+$0.00Bα+0.1BAILARD, INC.+$0.00Bα-0.0DIMENSIONAL FUND ADVISORS LP+$0.00Bα-0.4
Top-5 holders · 88.3%
RA CAPITAL MANAGEMENT, L.P.--
5AM Venture Management, LLC--
VR Adviser, LLC--
venBio Partners LLC--
FRANKLIN RESOURCES INC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
RA CAPITAL MANAGEMENT, L.P.9.9M5AM Venture Management, LLC2.4MVR Adviser, LLC1.6MvenBio Partners LLC531KCapital World Investors—FRANKLIN RESOURCES INC520KSamsara BioCapital, LLC—Woodline Partners LP—WELLINGTON MANAGEMENT GROUP LLP194KRTW INVESTMENTS, LP—
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (2 analysts)$37.5037290.0%
Last Year (2 analysts)$37.5037290.0%
Current Price$7.93
Analyst Ratings
4
Buy: 4Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$741K
9 txns · 5 insiders · 113,602 sh
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$75.00M
1 txn · 1 insider · 8,680,554 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-19 | SELL | Aslan Fred | director, officer: Chief Executive Officer | 27,116 | $9.01 | $244K | $13.83M |
| 2026-05-19 | SELL | Banerjee Subhashis | officer: Chief Medical Officer | 7,037 | $9.01 | $63K | $1.31M |
| 2026-05-19 | SELL | Bush Jennifer | officer: COO, CLO, Compliance Officer | 8,790 | $9.01 | $79K | $3.04M |
| 2026-05-19 | SELL | Horan Christopher | officer: Chief Tech Operations Officer | 7,002 | $9.01 | $63K | $2.64M |
| 2026-05-19 | SELL | Raymon Heather | officer: SVP, Research and Development | 3,095 | $9.01 | $28K | $1.34M |
| 2026-05-11 | BUY | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 8,680,554 | $8.64 | $75.00M | $131.36M |
| 2025-12-15 | SELL | Aslan Fred | director, officer: President and CEO | 3,187 | $6.00 | $19K | $7.26M |
| 2025-11-17 | SELL | Aslan Fred | director, officer: President and CEO | 6,375 | $3.38 | $22K | $1.16M |
| 2025-10-17 | SELL | Aslan Fred | director, officer: President and CEO | 25,500 | $6.00 | $153K | $2.14M |
| 2025-08-15 | SELL | Aslan Fred | director, officer: President and CEO | 25,500 | $2.73 | $70K | $1.06M |
Order Flow (FINRA, ~3w lag)
32.6%retail-7.2pp
16.8%dark+6.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Artiva Biotherapeutics: Accelerating Burn Rate and Strategic Insider Retreat
Overall Risk
6/10
Fraud
3/10
Dilution
7/10
Insolvency
6/10
Earnings Overstated
2/10
Hidden Liabilities
3/10
Legal
3/10
Audit Warnings
1/10
Hidden Upside
5/10
Contextually Acceptable
7/10